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 2011 National Lung Screening Trial demonstrates 
reduced morbidity and mortality with LDCT 
compared to CXR. 
 2013 USPSTF lung cancer screening guidelines 
updated.










 One lung cancer death prevented for every 320 
average risk patients screened with CT (vs CXR).
 20% of patients will have false positive findings 
requiring further evaluation. 
Amyloidosis:
 Amyloid in the tissue requires testing for subtype & 
systemic disease. 
 The AL amyloid subtype is associated with plasma 
cell dyscrasias. 
 Localized tracheobronchial amyloidosis is one of 


































70 year old female with PMHX of COPD who suffers 
from chronic dyspnea with exertion, and cough.
The patient has a 54 pack year smoking history, and 
quit smoking 2 years ago. In accordance with the 
























DDX: Central Airway Obstruction
Amyloid in the LungIncidental Central Airway Thickening Found on CTIntroduction
Tracheobronchial amyloidosis:
Deposits in trachea and bronchi. 
Usually localized. 




Nodular deposits. Localized. 
Associated with systemic B-cell 




Deposits in septa and vessel 
walls. AL or ATTRwt subtypes are 
most common. Systemic. 
Often asymptomatic.
This case explores one patient’s lung cancer screening, 
and the >$5,000 work up that followed. 
 Lung cancer screening can save lives but often with 
a cost. Physicians must educate patients about the 
risk of false positive results necessitating additional 
testing.
 To make a final diagnosis in this patient more testing 
was required with: bronchoscopy, pathology, mass 
spectrometry, SPEP, UPEP, serum free light chains, 
and a fat pad biopsy. 
 Her final diagnosis, localized tracheobronchial 
amyloidosis, is managed symptomatically with 
surgical treatments and stenting.
Bronchoscopy image. Pathology: Congo red stain & polarized light.




























free λ or κ
light chains
Mutated transthyretin 
(TTR), fibrinogen α chain


















USPSTF Guideline: Recommends “screening for lung 
cancer with low-dose computed tomography (LDCT) in 
adults aged 55 to 80 years who have a 30 pack-year 
smoking history and currently smoke or have quit within 
the past 15 years. Screening should be discontinued 
once a person has not smoked for 15 years or develops 
a health problem that substantially limits life expectancy 
or the ability or willingness to have curative lung 
surgery.”
Benefits:
 Higher cure rates. 
 Less invasive resection.
 Decreased rates of 
smoking. 
Harms
 False positive and 
incidental findings.




National Lung Cancer 
Screening Trial (NLST):
CXR vs. low radiation chest 
CT for lung cancer 
screening.
 Number needed to screen 
to prevent one lung cancer 
related death: 320
 20% reduction in relative 
lung cancer mortality.
 24% of LDCTs were 
abnormal. 96% of those, 
had false positive findings 
with 90% requiring further 
investigation. 
